MedCity News July 22, 2021
With a goal of making precision medicine the standard of care at health systems, Sema4 struck a nearly $800 million deal with CM Life Sciences to go public. The company, which offers tools that combine genomic and clinical data to glean patient care insights, will get $500 million in cash proceeds to grow its business.
Sema4, a company focused on providing genomic and clinical data insights, has gone public through a blank-check acquisition.
The company struck an approximately $800 million deal to merge with CM Life Sciences, a special-purpose acquisition company sponsored by affiliates of Casdin Capital, LLC, and Corvex Management LP. The deal will inject about $500 million into Sema4’s coffers.
The resulting combined company will begin trading on...
Today's Sponsors
Today's Sponsor